Business

Announcement on Inclusion of Global Registered Clinical Study on Zegfrovy in the Oral Presentation at the 2025 World Conference on Lung Cancer (WCLC) and the Selection of Multiple Studies In the Field of Non-Small Cell Lung Cancer

Announcement on Inclusion of Global Registered Clinical Study on Zegfrovy in the Oral Presentation at the 2025 World Conference on Lung Cancer (WCLC) and the Selection of Multiple Studies In the Field of Non-Small Cell Lung Cancer

articleDizal (jiangsu) Pharmaceutical Co. Ltd. Class AJuly 23, 20254/news/announcement-on-inclusion-of-global-registered-clinical-study-on-zegfrovy-in-the-oral-presentation-at-the-2025-world-conference-on-lung-cancer-wclc-and-the-selection-of-multiple-studies-in-the-field-of-non-small-cell-lung-cancer
Announcement on Inclusion of Global Registered Clinical Study on Zegfrovy in the Oral Presentation at the 2025 World Conference on Lung Cancer (WCLC) and the Selection of Multiple Studies In the Field of Non-Small Cell Lung Cancer

About this update from Dizal (jiangsu) Pharmaceutical Co. Ltd. Class A

Announcement on Inclusion of Global Registered Clinical Study on Zegfrovy in the Oral Presentation at the 2025 World Conference on Lung Cancer (WCLC) and the Selection of Multiple Studies In the Field of Non-Small Cell Lung CancerThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Dizal (jiangsu) Pharmaceutical Co. Ltd. Class A